In a large retrospective chart review of 500 NSCLC patients on PD-1- or PD-L-directed immunotherapy, daily aspirin use with anti-PD-L1 was associated with a higher likelihood of achieving complete remission (adjusted odds ratio = 1.85) [155]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.